Castle Biosciences (CSTL) Non-Current Deferred Tax Liability (2021 - 2026)

Castle Biosciences has disclosed Non-Current Deferred Tax Liability across 6 years of filings, most recently posting $2.3 million for Q1 2026.

• Non-Current Deferred Tax Liability for Q1 2026 came in at $2.3 million, up 177.78% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.3 million (up 177.78% YoY), and the FY2025 annual result was $2.3 million, down 90.39% from the prior year.
• Non-Current Deferred Tax Liability came in at $2.3 million for Q1 2026 at Castle Biosciences, roughly flat from $2.3 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $27.1 million in Q4 2022 to a low of $206000.0 in Q1 2024.
• The 5-year median for Non-Current Deferred Tax Liability is $1.6 million (2025), against an average of $6.0 million.
• Across the five-year window, Non-Current Deferred Tax Liability jumped 856.92% in 2024 and plunged 90.39% in 2025, its largest moves.
• Castle Biosciences' Non-Current Deferred Tax Liability stood at $27.1 million in 2022, then declined by 9.0% to $24.7 million in 2023, then dropped by 1.58% to $24.3 million in 2024, then slumped by 90.39% to $2.3 million in 2025, then dropped by 0.43% to $2.3 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $2.3 million (Q1 2026), $2.3 million (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.